Raloxiheal
✅ Supports bone health
✅ Reduces fracture risk
✅ Lowers cholesterol levels
✅ Prevents osteoporosis
✅ Menopause symptom relief
Raloxiheal contains Raloxifene.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
💡 Quick Answer
Raloxiheal is raloxifene 60 mg, a selective estrogen receptor modulator (SERM) with dual approval: prevention and treatment of postmenopausal osteoporosis, and reduction of invasive breast cancer risk in high-risk postmenopausal women. Unlike estrogen, raloxifene is NOT an HRT for hot flushes — it can worsen them. Safer breast-cancer profile than estrogen, but comparable VTE risk.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Every MedsBase order ships from a WHO-GMP certified manufacturer in plain, fully discreet packaging — nothing on the outside identifies the contents or the pharmacy. Card payments run through a regulated crypto on-ramp; the statement descriptor on your bank record is the processor name (a regulated card-payment processor) — never “MedsBase” or anything pharmacy-related. Crypto payments via Plisio stay fully anonymous. Every parcel is covered by our Reshipment Assurance Policy.
What Is Raloxiheal?
Raloxiheal is a branded generic of raloxifene 60 mg, a selective estrogen receptor modulator (SERM). SERMs have estrogen-like effects in some tissues and anti-estrogen effects in others. Raloxifene mimics estrogen in bone (positive — builds density) but blocks estrogen in breast tissue (positive — reduces breast cancer risk). It has neutral or mild effects on the uterus (unlike tamoxifen, which carries endometrial cancer risk). Manufactured by Healing Pharma.
FDA-Approved Indications
- Prevention of postmenopausal osteoporosis — typically in women 5+ years past menopause with moderate bone-density loss.
- Treatment of postmenopausal osteoporosis — reduces vertebral fracture risk by ~40–50% over 3 years.
- Reduction of invasive breast cancer risk in postmenopausal women at high risk. The STAR trial showed raloxifene 60 mg reduced invasive breast cancer risk ~50% (similar to tamoxifen) with fewer thromboembolic events and less endometrial cancer risk.
When Raloxifene Is Right For You
- You have: osteoporosis OR high breast cancer risk, age ≥60 or at least 5 years post-menopause
- You do not have: active hot flushes (raloxifene worsens them), VTE history, active liver disease, pregnancy potential
- Alternatives: bisphosphonates (alendronate, risedronate), denosumab, teriparatide for osteoporosis; tamoxifen as alternative SERM for breast cancer prevention (premenopausal option)
How to Take
- Take one 60 mg tablet once daily, at any time, with or without food.
- Take with adequate calcium (1000–1200 mg/day) and vitamin D (800–1000 IU/day) — raloxifene works better with sufficient bone substrate.
- Effects on bone density appear at 6–12 months; fracture risk reduction is continuous with ongoing use.
- Breast cancer risk reduction begins within months; maintained over years of use.
- Typical duration: 5 years for bone indications; up to 5 years for breast cancer risk reduction.
Side Effects
Common: hot flushes (new onset or worsening — up to 25%), leg cramps, peripheral oedema, flu-like symptoms, joint pain, sweating.
Less common: breast tenderness, depression, rash.
Serious (rare): VTE (DVT, PE) — risk similar to estrogen; fatal stroke in postmenopausal women with coronary heart disease (RUTH trial); retinal vein thrombosis.
Who Should Not Take Raloxiheal
- Active or history of VTE (DVT, PE) — raloxifene raises risk 2–3×
- Women with history of stroke (RUTH trial showed increased stroke fatality in women with coronary heart disease)
- Pregnancy or women who might become pregnant
- Children and adolescents
- Active liver disease
- Severe renal impairment
- Undiagnosed vaginal bleeding (investigate first)
- Active breast or endometrial cancer (discuss individually)
Raloxifene vs Alternatives — Decision Table
| Goal | First-line | Raloxifene’s role |
|---|---|---|
| Vasomotor (hot flush) relief | Estrogen / tibolone | Not indicated — worsens hot flushes |
| Postmenopausal osteoporosis | Alendronate / other bisphosphonates | Good alternative; strongest evidence for vertebral fracture |
| Breast cancer risk reduction | Tamoxifen (premenopausal) or raloxifene (postmenopausal) | Better side-effect profile than tamoxifen for postmenopausal use |
| Combined bone + breast cancer goals | Raloxifene | Single drug covers both |
Storage
Store at room temperature (15–25 °C). Keep in original blister, away from moisture and light. Keep out of reach of children.
Frequently Asked Questions
Is raloxifene the same as estrogen?
No — it is a selective estrogen receptor modulator (SERM). It acts like estrogen in bone (positive) but blocks estrogen in breast tissue (also positive, for cancer risk reduction). Uterine effect is neutral. Unlike estrogen, it does NOT treat hot flushes — it often worsens them.
Will raloxifene cause hot flushes?
Yes, in ~25% of users — either new-onset or worsening of existing flushes. This is the classic raloxifene trade-off: you get bone and breast protection but not symptom relief.
Can I combine raloxifene with estrogen?
No — combination negates the benefits. If you need hot flush relief AND bone protection, discuss options with a clinician: short-term estrogen first, then switch to raloxifene or bisphosphonate.
How long do I need to take Raloxiheal?
Typical courses are 3–5 years for osteoporosis; 5 years for breast cancer prevention. Longer duration is fine for ongoing osteoporosis protection.
What about calcium and vitamin D?
Yes — raloxifene works best combined with adequate calcium (1000–1200 mg/day) and vitamin D (800–1000 IU/day). These provide the substrate raloxifene helps retain.
Does raloxifene reduce hip fracture risk?
Trial data (MORE, CORE) show strong vertebral fracture reduction (~40–50%) but less conclusive effect on hip fracture. For hip-fracture-focused protection, bisphosphonates or denosumab may be preferred.
What is the VTE risk?
Raloxifene raises VTE risk ~2–3× (similar to estrogen). Risk is highest in the first 4 months. Stop raloxifene 3 days before prolonged immobilisation, surgery, or long flights; resume when mobile.
Is raloxifene safer than tamoxifen for breast cancer prevention?
For postmenopausal women, yes — raloxifene has lower endometrial cancer risk and fewer thromboembolic events vs tamoxifen, with similar invasive breast cancer risk reduction (STAR trial).
Related Hormone & Women’s Health Products
- Premarin (Conjugated Estrogens)
- Premarin Cream (Vaginal Estrogen)
- Progynova (Estradiol Valerate)
- Endogest (Progesterone 100 mg)
- Gestoford (Progesterone 100 mg)
- Gestheal (Progesterone 200 mg)
- Susten Capsule (Progesterone)
⚕️ Medical Disclaimer: Information is educational and does not replace medical advice. Hormone therapies carry specific risks (breast cancer, VTE, stroke, endometrial cancer if unopposed estrogen) — consult a clinician before starting, stopping, or changing any hormone medication. Individual risk–benefit depends on personal and family medical history.
Related Alternatives
Other products in Chronic Conditions that customers also view:
More options in Hormone Replacement Therapy (HRT) Medication for Menopause
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 60 mg |
|---|---|
| Quantity | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s, 400 Tablet/s, 800 Tablet/s |
Raloxiheal
Ερωτήσεις & Απαντήσεις
Raloxiheal
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές